Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 15.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of CollPlant Biotechnologies was 30.70% per year. The lowest was -274.30% per year. And the median was -18.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
CollPlant Biotechnologies 3-Year EBITDA Growth Rate Related Terms
FRA:CPT vs DRMA, AAGH, HCWB: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, CollPlant Biotechnologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CollPlant Biotechnologies 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where CollPlant Biotechnologies's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 15.80% mean?
CollPlant Biotechnologies (FRA:CPT) has a 3-Year EBITDA Growth Rate of 15.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CollPlant Biotechnologies and its competitors. According to the industry distribution chart, CollPlant Biotechnologies ranks #553 out of 1127 companies in the Biotechnology industry, placing it in the top 49.1%.
Is CollPlant Biotechnologies' 3-Year EBITDA Growth Rate too high?
CollPlant Biotechnologies' current 3-Year EBITDA Growth Rate is 15.80%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. CollPlant Biotechnologies' value of 15.80% is 6% above this industry median. Based on the distribution chart, CollPlant Biotechnologies ranks #553 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CollPlant Biotechnologies has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' 3-Year EBITDA Growth Rate compare to DRMA and AAGH?
According to the Biotechnology industry distribution chart, CollPlant Biotechnologies ranks #553 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts CollPlant Biotechnologies in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. CollPlant Biotechnologies' value of 15.80% is 6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CollPlant Biotechnologies's current 3-Year EBITDA Growth Rate of 15.80% is 6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CollPlant Biotechnologies and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CollPlant Biotechnologies's current 3-Year EBITDA Growth Rate is 15.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (FRA:CPT) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.23, compared to a current price of €0.27 — trading 15.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 15.80% and 6% above the Biotechnology industry median of 14.90. CollPlant Biotechnologies' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For CollPlant Biotechnologies (FRA:CPT), the current 3-Year EBITDA Growth Rate is 15.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CollPlant Biotechnologies (FRA:CPT) Overvalued in 2026?
Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued.
The current stock price of €0.27 is trading 15.7% above its estimated GF Value™ of €0.23.
GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.
Key valuation signals for FRA:CPT:
3-Year EBITDA Growth Rate: 15.80%
GF Value™: €0.23 vs. price of €0.27 (15.7% above fair value)
Industry Position: 6% above the Biotechnology median (#553 of 1127)
No single metric tells the full story. See the FRA:CPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
29GF Score
Get the complete analysis for FRA:CPT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CPT has been successfully added to your 
